Podcasts about prophylaxis

In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses Vijay Prasad's return to the FDA, revoking of COVID vaccine authorization for young children, the Legionnaires' outbreak in Harlem, the new labeling requirements for Ixchiq, the infectious attenuated Chikungunya vaccine and the importation of H5 influenza virus in Antarctica, before Dr. Griffin deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, guidelines for treating COVID-19, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, the association of “virus rebound” and post-acute sequelae among hospitalized patients, how virus infection particularly influenza and SARS-CoV-2 may ‘re-activate' dormant cancer cells and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Prasad returns to the FDA (Washington Post) Pfizer Covid vaccine for young children may not be renewed by FDA (The Guardian) Report suggests FDA may not reauthorize Pfizer COVID vaccine for young kids (CIDRAP) Factors Associated With Pediatric COVID-19 Mortality: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study (Journal of Pediatric Infectious Diseases Society) Legionnaires' Disease: In Harlem (NYC Health) Recommended Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated (FDA) FDA Removes Recommended Pause in Use and Approves Required Updated Labeling (FDA) Chikungunya Vaccines (CDC: Chikungunya virus) Chikungunya in China (CDC: Travelers' Health) Travelers' health notices (CDC: Travelers' Health) Areas at Risk for Chikungunya (CDC: Chikungunya virus) Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged ≥50 years (CID) Tracking HPAIV H5 through a geographic survey of Antarctic seabird populations (Scientific Reports) Report details first suspected H5 avian flu detections in seabirds in Antarctica(CIDRAP) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) ENFLONSIA: novel drug approvals 2025 (FDA) RSV-Network (CDC Respiratory Syncytial virus Infection) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness (CID) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Paxlovid (Pfizer) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID TWiV 1243: Capitalism, COVID and Cancer (MicrobeTV) Respiratory viral infections awaken metastatic breast cancer cells in lungs(Nature) Reaching out to US house representative Letters read on TWiV 1244 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Dominate C. diff! Learn to distinguish colonization from infection, select first-line therapies, and counsel patients on recurrence prevention and microbiome recovery. We're joined by IDSA past president and expert on foodborne and intestinal infections, Dr. Cindy Sears (Johns Hopkins University) for a comprehensive update on Clostridioides difficile (C. diff, Cdiff, CDAD, CDI). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Intro 03:00 Guest bio and hobby 04:25 Case of Charles Fleur Fontaine 06:00 Risk factors and epidemiology 08:00 Antibiotic hierarchy of risk 10:00 Diagnosis, testing strategies 14:00 Defining severity 17:30 Treatment options 20:00 Microbiome recovery strategies 24:00 Probiotics and postbiotics 27:00 Infection control counseling 30:00 C. diff and colon cancer 32:00 Recurrent C. diff strategies 35:00 Why some FMT and bezlotoxumab were discontinued 38:00 Microbiota replacement therapies 43:00 Prophylaxis strategies 45:00 Future therapies and ongoing research 47:00 Audience Q&A 52:00 Outro Credits Written and Produced by: Matthew Watto, MD, FACP  Cover Art and Infographic by: Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Cynthia Sears MD Disclosures Dr. Sears reports no relevant financial disclosures. Dr. Williams financial relationships disclosed include a Merck grant or research support. This relationship has not ended. Sponsor: Mint Mobile  This year, skip breaking a sweat AND breaking the bank. Get this new customer offer and your 3-month Unlimited wireless plan for just 15 bucks a month at mintmobile.com/CURB  Sponsor: Panacea Financial Let Panacea Financial take the financial stress off your plate,so you can get back to doing what matters most. Visit panaceafinancial.com  Sponsor: FIGS Get15% off your first order at wearfigs.com with the code FIGSRX

Healthcare professionals and Private Sector Providers recently got the opportunity to participate in a workshop on the use and prescribing of Pre-Exposure Prophylaxis (PrEP). The workshop was aimed at building the capacity and knowledge of participants on PrEP and to also take a look at the proper practices for prescribing the medication, explore key indications for PrEP use and also discuss some of the communication strategies for interacting with clients. The medication PrEP is a highly effective medication which is used to prevent HIV transmission. 

Justin Coleman talks to Kate McKenzie, General Practitioner and member of one of the Antibiotic Expert Groups, in part 2 of our series on the latest updates to Therapeutic Guidelines: Antibiotic. This episode focuses on changes to guidance for primary care, including new recommendations for UTIs, infectious diarrhoea, bronchiectasis, infections of diabetes-related foot ulcers and much more.

In this episode of the HAE Speaks Podcast, Dr. Raffi Tachdjian (UCLA) and Pharvaris discuss the HAE CHAPTER-3 Study — a new HAE attack prevention trial currently enrolling. The study explores the safety and effectiveness of deucrictibant, an investigational once-daily oral treatment aimed at preventing HAE attacks.Thank you to Pharvaris for sponsoring this episode of the HAE Speaks Podcast!

The FDA approved lenacapavir, a twice-yearly injectable PrEP shown to be 99% effective in preventing HIV, though high cost may limit global access. A phase 3 trial found that adding pembrolizumab to standard care improved event-free survival in head and neck cancer, especially in patients with high PD-L1 expression. MASLD-related deaths in the U.S. have quadrupled since 2006, rising most sharply in older adults and rural areas, and are expected to continue increasing.

In this episode, Callum and Jame discuss the latest evidence base for endocarditis assessment & management, focusing on the ESC 2023 guidance. Epidemiology! Prophylaxis! How to take a blood culture! A long and complicated comparison of the Duke-ISCVID and Duke-ESC criteria that doesn't really matter because they're both as good as each other! AND MORE…in part 2 because this is a 2-parter sorry SEE YOU NEXT TIME! Show notes for this episode here: https://idiots.notion.site/111-112-Endocarditis-2023-Update-3594d55559314434a3b87d4c30ec41f3 Send us a text Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on Bluesky @idiots-pod.bsky.socialPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod

Credits: 0.50 AMA PRA Category 1 Credits™, 0.50 ABIM MOC or 0.52 AANP including 0.52 AANP Pharm   CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/Podcast/post-exposure-prophylaxis-covid-19  Overview: Explore the evolving role of post-exposure prophylaxis (PEP) for COVID-19 in high-risk populations. Join infectious disease experts from Johns Hopkins as they discuss the latest data, clinical considerations, and promising agents in reducing severe outcomes when vaccination alone may not be enough. 

Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.

Episode Notes In this episode, DASON Clinical Pharmacist Liaison Dr. Angelina Davis chats with us about several articles about antibiotic prophylaxis for spontaneous bacterial peritonitis (SBP) in patients with cirrhosis. The materials reviewed in this episode can be found on the DASON Digest page on our website: https://dason.medicine.duke.edu/blog/sbp-prophylaxis-what-were-doing-why-were-doing-it-and-should-we-keep-doing-it For more information about DASON, please visit: https://dason.medicine.duke.edu/

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is responsible for 9–30% of pregnancy-related mortality in high resource countries and remains a significant, increasing cause of severe maternal morbidity. Peripartum, 50% of VTE events occur in the postpartum interval, which has a 6-fold higher risk compared to antepartum. There is wide variation in LMWH pharmacological postpartum prophylaxis guidance. The RCOG, for example, recommends 10 days of LMWH for all postop CS patients unless it was elective, and additional risk factors exist. The ACOG uses a more selective approach. However, on Jan 16, 2025, a new multicenter retrospective study from the US is raising questions about the efficacy of postpartum VTE pharmacologic therapy. Is there really no need for pp VTE pharmacologic therapy? Or does the answer lie in the reality of VTE as a “low frequency, high acuity” event? Listen in for details!

Send us a textGrab your trainers, your dog lead, or a cuppa and join us for some free CPD as we have another relaxed round up of recent Red Whale primary care Pearls of wisdom.  In the first of two episodes this month, Ali and Nik discuss: 3% of adults presenting to primary care with an acute cough have pertussis, but would you spot it?What is our role in primary care if a patient approaches us for advice about antibiotic prophylaxis for STIs?Listen as soon as you can to ensure you have full access to all the free resources. The rest of the Pearls from December will be covered next week along with a new best intentions story to put a smile on your face.Pertussis BMJ 2019;364:l401 UKHSA Guidance on the management of cases of pertussis in England during the re-emergence of pertussis in 2024 Whooping Cough Net - symptoms (examples of full-blown whooping cough and attenuated forms in immunised individuals. Also information for patients about why treatment is ineffective. Site by Doug Jenkinson, a GP in ( Nottinghamshire) Testing guidelines from the UKHSA can be found here. The Green Book on PertussisProphylaxis for sexually transmitted infections BASHH Position statement on Doxycycline as Prophylaxis for Sexually Transmitted Infections 2021 The IPERGAY trial (Lancet Inf Diseases 2018;18(3):308) CDC guidance 1 Send us your feedback podcast@redwhale.co.uk or send a voice message Sign up to receive Pearls here. Pearls are available for 3 months from publish date. After this, you can get access them plus 100s more articles when you buy a one-day online course from Red Whale OR sign up to Red Whale Unlimited. Find out more here. Follow us: X, Facebook, Instagram, LinkedInDisclaimer: We make every effort to ensure the information in this podcast is accurate and correct at the date of publication, but it is of necessity of a brief and general nature, and this should not replace your own good clinical judgement, or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular, check drug doses, side-effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in this podcast....

Case Discussion 120: VTE prophylaxis

Interview with Stephanie E. Cohen, MD, author of Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends, and guest discussant JAMA Deputy Editor Preeti Malani, MD, MSJ. Hosted by Eve Rittenberg, MD. Related Content: Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends

Interview with Stephanie E. Cohen, MD, author of Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends, and guest discussant JAMA Deputy Editor Preeti Malani, MD, MSJ. Hosted by Eve Rittenberg, MD. Related Content: Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends

What is the proper coding for a prophylaxis and how does that change with supra and sub gingival scaling.  Enjoy an open discussion with Kathy Forbes as she shares her wealth of knowledge on the descriptions used to define codes.  Where is your CDT guide?

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CJB865. CME credit will be available until November 16, 2025.The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CJB865. CME credit will be available until November 16, 2025.The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CJB865. CME credit will be available until November 16, 2025.The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CJB865. CME credit will be available until November 16, 2025.The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CJB865. CME credit will be available until November 16, 2025.The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CJB865. CME credit will be available until November 16, 2025.The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CJB865. CME credit will be available until November 16, 2025.The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Even though highly effective medications are currently available to prevent HIV, there are about 1.3 million new infections worldwide each year. Monica Gandhi, MD, MPH, of the University of California San Francisco joins JAMA Senior Editor Karen E. Lasser, MD, MPH, to discuss preexposure prophylaxis (PrEP) for HIV. Related Content: Preexposure Prophylaxis (PrEP) for HIV What Is Doxycycline Postexposure Prophylaxis?

In this episode, we review the recommendations from the 2024 SCCM/ASHP stress ulcer prophylaxis guidelines and highlight three of the more recent landmark critical care trials investigating the role of stress ulcer prophylaxis. Key Concepts After 25 years, the stress ulcer prophylaxis guidelines have been updated by SCCM and ASHP. These guidelines make 13 recommendations in a PICO format. Three large, landmark randomized controlled trials (SUP-ICU, PEPTIC, and REVISE) have significantly contributed to the body of literature regarding stress ulcer prophylaxis. The SCCM/ASHP guidelines recommend stress ulcer prophylaxis in patients with coagulopathy, shock, chronic liver disease, and possibly in neurocritical care patients. They do not specifically recommend prophylaxis in mechanically ventilated patients; this is a controversial recommendation. The SCCM/ASHP guidelines equally prefer proton pump inhibitor (PPI) and histamine-2 receptor antagonists (H2RA) drug therapies given either intravenously or orally. The prophylaxis regimen should be continued until the indication for prophylaxis has resolved or the patient leaves the ICU. References MacLaren R, Dionne JC, Granholm A, et al. Society of Critical Care Medicine and American Society of Health-System Pharmacists Guideline for the Prevention of Stress-Related Gastrointestinal Bleeding in Critically Ill Adults. Crit Care Med. 2024;52(8):e421-e430. doi:10.1097/CCM.0000000000006330 SUP-ICU study. Krag M, Marker S, Perner A, et al. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. N Engl J Med. 2018;379(23):2199-2208. doi:10.1056/NEJMoa1714919 PEPTIC study. PEPTIC Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group, Alberta Health Services Critical Care Strategic Clinical Network, and the Irish Critical Care Trials Group, Young PJ, Bagshaw SM, et al. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. JAMA. 2020;323(7):616-626. doi:10.1001/jama.2019.22190 REVISE study. Cook D, Deane A, Lauzier F, et al. Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation. N Engl J Med. 2024;391(1):9-20. doi:10.1056/NEJMoa2404245

The Society of Critical Care Medicine just released their first set of updated stress ulcer prophylaxis (SUP) guidelines since 1999 that include groundbreaking changes. We also discuss evidence on proton pump inhibitor (PPI) use for SUP that impacts ICU practice.  The GameChangerNew guidelines for use of PPIs for stress ulcer prophylaxis will have a significant impact on ICU practice.HostJen Moulton, BSPharmPresident, CEimpactGuest Geoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthMatthew Trump, DO, FACP, FCCPPulmonologistThe Iowa ClinicReferenceGuidelinesPaperPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the new Stress Ulcer Prophylaxis (SUP) guidelines from the Society of Critical Care Medicine (SCCM), including identifying patients at risk.2. Discuss the use of Proton Pump Inhibitors (PPI) and Histamine-2 Receptor Antagonists (H2RA) for Stress Ulcer Prophylaxis (SUP).0.05 CEU/0.5 HrUAN: 0107-0000-24-247-H01-PInitial release date: 08/26/2024Expiration date: 08/26/2025Additional CPE details can be found here.

The Society of Critical Care Medicine just released their first set of updated stress ulcer prophylaxis (SUP) guidelines since 1999 that include groundbreaking changes. We also discuss evidence on proton pump inhibitor (PPI) use for SUP that impacts ICU practice.  The GameChangerNew guidelines for use of PPIs for stress ulcer prophylaxis will have a significant impact on ICU practice. GuestGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthMatthew Trump, DO, FACP, FCCPPulmonologistThe Iowa Clinic ReferenceGuidelinesPaper Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the new Stress Ulcer Prophylaxis (SUP) guidelines from the Society of Critical Care Medicine (SCCM), including identifying patients at risk.2. Discuss the use of Proton Pump Inhibitors (PPI) and Histamine-2 Receptor Antagonists (H2RA) for Stress Ulcer Prophylaxis (SUP).0.05 CEU/0.5 HrUAN: 0107-0000-24-247-H01-PInitial release date: 08/26/2024Expiration date: 08/26/2025Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Show notes at pharmacyjoe.com/episode944. In this episode, I'll discuss the new SCCM and ASHP joint guidelines on stress ulcer prophylaxis in critically ill patients. The post 944: Stress Ulcer Prophylaxis – A Guideline Update 25 Years in the Making appeared first on Pharmacy Joe.

Case Discussion 117 Answer: VTE prophylaxis in hospitalized patients

Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In this podcast series, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.Launch Date: July 26, 2024Release Date: July 26, 2024Expiration Date: June 30, 2025FACULTYTimothy Craig, DO, FAAAAI, FACP, FACAAI, FACOITenured Professor of MedicinePediatrics and Distinguished EducatorPennsylvania State UniversityMarc Riedl, MD, MSProfessor of MedicineUniversity of California, San DiegoClinical Director - US HAEA Angioedema CenterUniversity of California, San DiegoThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-centered-approaches-to-long-term-prophylaxis-in-hae-1

Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In this podcast series, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.Launch Date: July 26, 2024Release Date: July 26, 2024Expiration Date: June 30, 2025FACULTYTimothy Craig, DO, FAAAAI, FACP, FACAAI, FACOITenured Professor of MedicinePediatrics and Distinguished EducatorPennsylvania State UniversityMarc Riedl, MD, MSProfessor of MedicineUniversity of California, San DiegoClinical Director - US HAEA Angioedema CenterUniversity of California, San DiegoThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-centered-approaches-to-long-term-prophylaxis-in-hae-1

Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In this podcast series, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.Launch Date: July 26, 2024Release Date: July 26, 2024Expiration Date: June 30, 2025FACULTYTimothy Craig, DO, FAAAAI, FACP, FACAAI, FACOITenured Professor of MedicinePediatrics and Distinguished EducatorPennsylvania State UniversityMarc Riedl, MD, MSProfessor of MedicineUniversity of California, San DiegoClinical Director - US HAEA Angioedema CenterUniversity of California, San DiegoThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-centered-approaches-to-long-term-prophylaxis-in-hae-1

Editor's Summary by Anthony Charles, MD, MPH, Associate Editor of JAMA, the Journal of the American Medical Association, for the July 23/30, 2024, issue.

In part one of this series on anthrax, Lynne will answer last week's question about why scientists in the second half of the 1800s were so interested in studying the bacteria responsible for anthrax. But also, she will explain how the bacteria works, how it can infect humans, how it causes life-threatening and fatal illness, and how it is treated. As a bonus, Helen explains the terms “gram positive” and “gram negative” bacteria.   Special note: Dr. Helen Shui is truly a doctor, but is working under a pseudonym for privacy reasons. Dr. Lynne Kramer is using her real name.  Music by Helen Shui and Caplixo. Cover art by Lynne Kramer.  Sources: Anthrax: A disease of biowarfare and public health importance by Ajay Kumar Goel Review of anthrax: A disease of farm animals by Emtaj Alam MD et. al. Current Status and Trends in Prophylaxis and Management of Anthrax Disease by Vladimir Savransky, Boris Ionin, and Joshua Reece Please contact us with questions/concerns/comments at defunctdoctorspodcast@gmail.com. @defunctdoctorspodcast on Instagram, Facebook, X (Twitter), Threads, YouTube, and TikTok  Follow Lynne on Instagram @lynnedoodles555

VTE prophylaxis is more than just some squeezy leg socks and a one-size fits all dose of enoxaparin!  Ever wonder how VTE prophylaxis is similar to constipation?  Have you or a loved one been hurt by a hospital administrator telling you that VTE is a never event?  Come with us, and our special guest Dr. Bryan Cotton, on this journey to the frontier of research attempting to debunk this myth and improve patient care by reducing VTE rates in trauma patients.   Hosts: - Michael Cobler-Lichter, MD, PGY4/R2: University of Miami/Jackson Memorial Hospital/Ryder Trauma Center @mdcobler (X/twitter) - Eva Urrechaga, MD, PGY-8, Vascular Surgery Fellow University of Pennsylvania Recent graduate of University of Miami/Jackson Memorial Hospital/Ryder Trauma Center General Surgery Residency @urrechisme (X/twitter) - Eugenia Kwon, MD, Trauma/Surgical Critical Care Attending: Loma Linda University Recent graduate of University of Miami/Jackson Memorial Hospital/Ryder Trauma Center Trauma/CC Fellowship - Brandon Parker, DO, Assistant Professor of Surgery, 5 years in practice University of Miami/Jackson Memorial Hospital/Ryder Trauma Center @BrandonParkerDO (X/twitter) - Bryan Cotton, MD, MPH, FACS, Professor of Surgery, 20 years in practice  University of Texas Health Science Center at Houston/Red Duke Trauma Institute at Memorial Herman Hospital @bryanacotton1 (X/twitter) Learning Objectives: - Describe the rationale for the addition of aspirin to chemoprophylactic regimens for VTE -  Identify appropriate screening systems for trauma patients at high risk for VTE -  Describe the rationale for monitoring anti factor Xa levels in the trauma population receiving VTE chemoprophylaxis - List the major conclusions of the two studies discussed regarding the addition of aspirin to VTE chemoprophylaxis regimens in trauma patients, and the change in antithrombin activity levels over time in relation to enoxaparin responsiveness in polytrauma patients Quick Hits: 1.     On adjusted analysis, the standard VTE PPX plus aspirin group had a lower OR of developing VTE, though limitations of this study highlight need for future prospective work 2.     Trauma patients often suffer from decreased activity of antithrombin 3, which may mediate the relatively higher rates of VTE in this population. 3.     Trauma patients who went on to develop VTE were more likely to not achieve satisfactory anti Xa levels, with a VTE rate of 30% in the never-responder group, the group for which Xa levels were never higher than 0.2 4.     Ex vivo supplementation of antithrombin seems to improve enoxaparin responsiveness.  Remember, enoxaparin and heparin are HELPING AT3, not the other way around References 1.     Lammers D, Scerbo M, Davidson A, et al. Addition of aspirin to venous thromboembolism chemoprophylaxis safely decreases venous thromboembolism rates in trauma patients. Trauma Surg Acute Care Open. 2023;8(1):e001140. doi:10.1136/tsaco-2023-001140 https://pubmed.ncbi.nlm.nih.gov/37936904/ 2.     Vincent LE, Talanker MM, Butler DD, et al. Association of Changes in Antithrombin Activity Over Time With Responsiveness to Enoxaparin Prophylaxis and Risk of Trauma-Related Venous Thromboembolism. JAMA Surg. 2022;157(8):713-721. doi:10.1001/jamasurg.2022.2214 https://pubmed.ncbi.nlm.nih.gov/35731524/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

In this episode of "ASTCT Talks," Dr. Shernan Holtan sits down with Dr. Samer Al-Homsi, as he shares his insights on the future of graft versus host disease (GVHD) prophylaxis, particularly in haploidentical transplantation. Dr. Al-Homsi delves into the innovative CAST regimen, which combines post-transplant cyclophosphamide, abatacept and short-duration tacrolimus. Learn about the challenges, breakthroughs and promising results that could revolutionize how we approach GVHD prevention and treatment, making a future without GVHD a reality. Listen in as we explore the potential for reducing transplant toxicities and the impact on patient care. About Dr. Samer Al-Homsi A. Samer Al-Homsi, MD, MBA, is the System Chief of Blood and Marrow Transplant and Cellular Therapy at Northwell Health Cancer Institute and serves as Director of Faculty and Academic Affairs in Medical Oncology. He is a Professor of Medicine at the Zucker School of Medicine and of Cancer Research at Feinstein Institutes of Medical Research. Previously, he was the Executive Director of Blood and Marrow Transplantation at NYU Grossman School of Medicine. Dr. Al-Homsi graduated from Damascus Medical School and trained in Hematology and Medical Oncology in France. He completed his residency at Advocate Health Care and fellowship at the University of Massachusetts. He has led programs in Malignant Hematology and Blood and Marrow Transplantation at several institutions, including NYU Langone Health. His research focuses on preventing graft-versus-host disease (GvHD), developing innovative approaches such as the CyBor and CAST regimens, particularly in haploidentical transplants. Dr. Al-Homsi aims to address healthcare disparities due to donor shortages among minority groups. Dr. Al-Homsi is also the President of the American Arab Assembly of Cellular Therapy and Transplantation (AAACTT), promoting collaboration among its members. About Dr. Shernan Holtan Dr. Holtan is a clinical/translational investigator. Her work focuses on increasing resilience, both at the tissue level to prevent and treat GVHD, and at the whole person level, designing exercise programs to mitigate cancer therapy-associated aging. In GVHD, her early work focused on epidermal growth factor and pregnancy hormones to facilitate tissue repair in GVHD, which led to a successful phase II study for the treatment of high-risk acute GVHD and discovery of the GVHD biomarker amphiregulin. More recently, she has led and published two prospective clinical trials regarding the use of PTCy as GVHD prophylaxis, the results of which are changing practice around the globe. Dr. Holtan has also been a competitive powerlifter, setting a national record in 2019. She has leveraged her knowledge regarding strength training into translational studies and clinical trials that are helping to reverse some of the damage done by high-dose chemotherapy and radiation. Through her multidimensional accomplishments, Dr. Holtan has demonstrated a unique and powerful intersection of medical research and physical resilience, redefining standards of care in HCT, and innovatively combating the deleterious effects of cancer treatment.

Show notes at pharmacyjoe.com/episode932. In this episode, I'll discuss recent articles regarding stress ulcer prophylaxis. The post 932: Major Developments in Stress Ulcer Prophylaxis Evidence appeared first on Pharmacy Joe.

Lauren Metropulos, PharmD will review seizure prophylaxis in traumatic brain injury.   For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

In this week's episode we'll learn about fitusiran prophylaxis in patients with hemophilia A or B, with or without inhibitors. Next we'll hear about new findings that heterozygous germline variants in the NBN gene that are linked to increased risk of B-cell acute lymphoblastic leukemia in children. Finally, we'll explore new insights on the histone demethylase PHF8, which has been identified as a master regulator of cell-intrinsic immune responses in acute myeloid leukemia. Featured Articles:Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trialGermline genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia

For the latest episode in our Hot Topics series, Dr Nicholas Morris, FCNS is joined by Dr Jennifer Frontera, FNCS to discuss the NCS Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury.  Download the guidelines at https://link.springer.com/article/10.1007/s12028-023-01907-x. 

Self-administered device cleared to treat stress urinary incontinence in women; Autoinjector warning for relapsing MS treatment; COVID-19 preexposure prophylaxis investigational treatment looks promising; Biosimilars for Eylea approved; Imdelltra approved for extensive stage small cell lung cancer with disease progression.  

This week, Marianna sits down with Dr. Joseph McGowan to talk about DoxyPEP - or Doxycycline for Post-exposure Prophylaxis - as prevention for sexually transmitted infections. Tune in to hear all about what this is, how it's being used, and the latest guidance for healthcare providers. --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=EAY6574)-- Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. Check out our free online courses: www.necaaetc.org/rise-coursesDownload our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

Kennedy Concannon, PharmD discusses cytomegalovirus prophylaxis in solid organ transplantation. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

This week we delve into the world of antibiotic prophylaxis for dental procedures. What are the data to support its use in the congenital heart patient? Why has this been such a difficult topic to study? What do we now know about this topic and what still remains unanswered? Given the low prevalence but dire consequences of this disease, how can investigators consider studying this topic in the future? Is there adequate equipoise to proceed with a randomized controlled trial? We speak with Advanced Imaging Fellow at Boston Children's Hospital, Dr. Francesca Sperotto of Harvard University about her recent multicenter meta-analysis of 30 studies including over one million cases of endocarditis. DOI: 10.1001/jamacardio.2024.0873

Today on the Marko and Andy Power Hour these two cobbers just watched Mega Force and spoiler alert… it sucked. We get an update on Andy's arcade machine build, more retro game emulator talk, and Marko loves Pseudoephedrine. Nothing will ever be the same as Marko is shocked by Andy's startling Goldeneye revelation! Plus the old man hosts listen to some awesome music! If you like what you're hearing you can support Beyond Synth on Patreon: www.patreon.com/beyondsynth or PayPal: www.paypal.com/paypalme/beyondsynth Don't Forget to Check out ALL the artists featured on the show: Echo Wolf - “Contender” https://soundcloud.com/echowolfmusic https://echowolf.bandcamp.com https://www.instagram.com/echowolfmusic/ https://open.spotify.com/artist/60ZQkaf0EkOhPZOKlwYv5s https://twitter.com/echo_wolf_music/ Isaac Howlett - “House of Cards” https://soundcloud.com/isaachowlett https://isaachowlett.bandcamp.com/album/house-of-cards https://open.spotify.com/artist/5o7ehDTnABXbhjnIbM2J6r https://www.instagram.com/isaachowlett/ https://www.facebook.com/Isaac.Howlett.Music/ Fear of Tigers - “You've Found Love” https://soundcloud.com/fearoftigers http://fearoftigers.bandcamp.com https://open.spotify.com/artist/2eMdch9qwgd4eJoU4Wgsuy https://www.instagram.com/fearoftigers/?hl=en https://www.facebook.com/fearoftigers/ Vincenzo Salvia - “My sign (Feat. Vanessa K.)” https://soundcloud.com/vincenzo-salvia http://vincenzosalvia.bandcamp.com/ https://open.spotify.com/artist/0B1OIGHmTqq2gEn4IMaEci https://www.instagram.com/vincenzosalvia/ https://www.facebook.com/vincenzosalviamusic AWITW - “Marion (feat. Ross Lustre)” https://soundcloud.com/awitw https://awitw.bandcamp.com/ https://open.spotify.com/artist/6FCsiGlQ06DlR5FE6skY6U https://www.instagram.com/a.w.i.t.w/ Ross Lustre: https://www.instagram.com/thelustre/ https://open.spotify.com/artist/33P1TVmBTLSediKiNH5oV0 Dug Masters - “Obsesión” https://soundcloud.com/dug-masters https://dugmasters.bandcamp.com/ https://open.spotify.com/artist/0q0izMxiBKw2W3cxiX5JAk https://www.instagram.com/holibeer24/ https://www.youtube.com/user/holibeeratown/videos Emil Rottmayer - “Radiate” https://soundcloud.com/emil-rottmayer https://emilrottmayer.bandcamp.com/ https://open.spotify.com/artist/2UuvaSzB0VNumArR71ReMT https://www.instagram.com/emil_rottmayer/ QNAUT - “Simulacrum (feat. Prophylaxis)” https://soundcloud.com/qnaut https://qnaut.bandcamp.com https://www.instagram.com/qnaut.media https://open.spotify.com/artist/26ym7b1Caos9POuPfjqe4S https://www.youtube.com/channel/UCdHHJ1JmQd6qPxT05APVubQ Prophylaxis: https://soundcloud.com/prophylaxis-797304334 https://prophylaxis2077.bandcamp.com/music https://www.instagram.com/prophylaxis_2020/ https://open.spotify.com/artist/7oZrPKCw4bveJMORcP4Iep https://www.youtube.com/channel/UCN3w_0fJvj7HhgsboVoVwUw Gridluster - “Phonecalls From T O K Y O” https://gridluster.bandcamp.com/ https://www.instagram.com/gridlustermusic/ https://open.spotify.com/artist/1vIC7jAkcNX2KtPcl14qrg Bunny X & Sandor Gavin - “Daydreaming (Sandor Gavin Remix)” https://soundcloud.com/bunny-x https://bunnyx.bandcamp.com/ https://open.spotify.com/artist/1Jm30qu7cd4QfXkJSoYL6y https://www.instagram.com/bunny_xmusic/ Sandor Gavin: https://soundcloud.com/sandorgavin https://sandorgavin.bandcamp.com/ https://open.spotify.com/artist/3WdYHvFVTB7OeUODdtrSfM https://www.instagram.com/sandorgavin/ https://www.youtube.com/user/sandorgavin Martin Matiske - “Dimension Phantasy (Oh Lord! Remix By Play Paul)” https://soundcloud.com/martin-matiske https://bordelloaparigi.bandcamp.com/album/dimension-phantasy https://www.instagram.com/martin_matiske/ https://www.youtube.com/channel/UCQSlG1fAUoNAkXh5xhBKhxA Play Paul: https://soundcloud.com/playpaulmusic https://www.instagram.com/play__paul/ https://open.spotify.com/artist/7lIIilMB5xwbRUeZY6QfuQ

Join us as we review recent articles and news featured in The DIGEST #48, #49, and #50 including thromboprophylaxis for patients receiving chemotherapy,  eosinophil count to guide steroids in COPD exacerbations, anticoagulation in subclinical atrial fibrillation, the new genetic testing recommendations for patients with breast cancer, and at-home STI testing–not to mention trial names galore.  Fill your brain hole with a fully digestible meal! Featuring Paul Williams (@PaulNWilliamz), Nora Taranto (@norataranto) and Matt Watto (@doctorwatto).  Claim CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | CME! Credits Written and Hosted by: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Nora Taranto MD  Reviewer: Emi Okamoto MD  Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments 00:00 Introduction + Pun  06:06 Target TP Trial: Thromboprophylaxis in Cancer Patients 13:07 Steroids for COPD Exacerbations 25:25 Anticoagulation in Subclinical Atrial Fibrillation 34:01 Genetic Testing in Breast Cancer 43:38 Home STI Testing Transcript Disclaimer We've included a a free AI-generated transcript which has not been corrected by a human for accuracy or completeness. Please consider this a starting point for further research and consultation. We disclaim any liability for damages or losses resulting from this content. Sponsor: Factor Head to FactorMeals.com/curb50 and use code curb50 to get 50% off.  Sponsor: NetSuite Download NetSuite's popular KPI Checklist, designed to give you consistently excellent performance - absolutely free, at NetSuite.com/CURBSIDERS. Sponsor: Freed  You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month.

Show notes at pharmacyjoe.com/episode880. In this episode, I'll discuss anti-Xa monitoring of enoxaparin in VTE prophylaxis. The post 880: Anti-Xa Monitoring In VTE Prophylaxis: Just Because We Can Doesn’t Mean We Should appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode880. In this episode, I ll discuss anti-Xa monitoring of enoxaparin in VTE prophylaxis. The post 880: Anti-Xa Monitoring In VTE Prophylaxis: Just Because We Can Doesn’t Mean We Should appeared first on Pharmacy Joe.